What is a typical safety consideration when using SGLT2 inhibitors in heart failure?

• A. They have no HF benefit.
• B. They worsen volume status significantly.
• C. They cause severe hypoglycemia.
• D. Improve outcomes; monitor for genitourinary infections and volume status; generally well tolerated.

Answer: (D)

SGLT2 inhibitors in heart failure improve outcomes, including fewer heart failure hospitalizations and cardiovascular events, across different types of heart failure. Because these drugs cause osmotic diuresis and glucosuria, the safety focus is on monitoring volume status (to avoid overdiuresis) and watching for genitourinary infections. They’re generally well tolerated and do not commonly cause severe hypoglycemia, especially in patients without diabetes or not on insulin or secretagogues. So, the typical safety consideration is to monitor for genitourinary infections and volume status while recognizing the overall HF benefit.